Angle shares jump on cell harvesting update

Shares in Angle, a specialist medtech company, leapt 20 per cent on Monday after the group said it has extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function.

Shares in Angle, a specialist medtech company, leapt 20 per cent on Monday after the group said it has extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function.

Harvesting is where captured tumour cells are recovered from the Parsortix cassette for molecular analysis.

The company's Founder and Chief Executive, Andrew Newland, said: "We have seen widespread demand from researchers and clinicians for circulating tumour cells to be made available in a test tube after isolation from blood.

"It is testimony to the versatility of our separation technology that we have been able to introduce and automate this capability in such a short time. The consequent prospects for our Parsortix sales are significant."

The Parsortix system's ability to harvest cells for analysis is seen as a major advantage and key competitive differentiator, the group explained. Because of this, top cancer research centres and hospitals currently in discussions with the company have all emphasised the importance of this harvesting capability in meeting a key unmet medical need.

The company added: "The Parsortix system now has the potential to provide users with cancer cells for analysis from a simple blood test - a form of "liquid biopsy". This opens the way for the cells to be analysed to identify the specific mutations of the individual patient's cancer using a wide range of genetic and molecular techniques.

"This then offers the prospect of personalised medicine with drugs and other treatment selected specifically to address the individual patient's own cancer with better patient outcomes and lower costs of treatment."

The share price climbed 21.11% to 54.50p by 15:05 on Monday.

NR

Recommended

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022
Delivering profits: should you buy Royal Mail shares?
Share tips

Delivering profits: should you buy Royal Mail shares?

The volume of parcels delivered by Royal Mail soared during the pandemic, and so did its profits. But it has been coming under pressure lately. So, as…
19 May 2022

Most Popular

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Aviva: a share for income investors to tuck away
Share tips

Aviva: a share for income investors to tuck away

Insurance giant Aviva is one of the highest yielding stocks in the FTSE 100 – and it’s cheap, too, making it a tempting target for income investors. R…
18 May 2022
Despite the crypto crash, bitcoin still has a bright future
Bitcoin & crypto

Despite the crypto crash, bitcoin still has a bright future

Cryptocurrencies have crashed hard, with bitcoin down by more than 50% from its peak. But, says Dominic Frisby, bitcoin still has a future – it is the…
19 May 2022